Clinical characteristics |
Age >65 years |
0.59 (0.46–0.76)*** |
0.77 (0.69–0.86)*** |
Male sex (n=5413) |
|
1.19 (1.08–1.32)*** |
Body weight <75 kg |
|
1.12 (1.02–1.24)* |
Initial presentation |
Pulse >110 beats per min (n=2214) |
0.33 (0.23–0.48)*** |
0.62 (0.55–0.71)*** |
Systolic BP levels <100 mmHg (n=888) |
0.50 (0.26–0.93)* |
|
Temperature <36°C (n=756) |
|
0.82 (0.68 - -0.99) * |
Risk factors |
Cancer (n=2550) |
2.55 (2.00–3.27)*** |
1.30 (1.16–1.45)*** |
Immobility ≥4 days (n=1663) |
|
0.82 (0.71–0.95)** |
Oestrogen therapy (n=630) |
|
1.68 (1.37–2.07)*** |
Underlying conditions |
Chronic heart failure (n=931) |
|
0.74 (0.61–0.89)** |
Chronic lung disease (n=1598) |
|
0.80 (0.70–0.92)** |
Creatinine clearance levels <60 mL·min−1(n=3963) |
|
0.81 (0.72–0.91)*** |
Countries |
Spain (n=8270) |
Ref.*** |
Ref.*** |
Italy (n=593) |
5.17 (3.11–8.58)*** |
|
France (n=964) |
0.48 (0.25–0.90)* |
|
Israel (n=429) |
0.36 (0.13–0.97)* |
2.12 (1.68–2.67)*** |
Other countries (n=1217) |
11.50 (9.02–14.66)*** |
2.25 (1.93–2.62)*** |
Initial therapy |
LMWH (n=9935) |
Ref.*** |
Ref.*** |
Unfractionated heparin (n=647) |
0.16 (0.07–0.35)*** |
0.36 (0.28–0.46)*** |
Thrombolytics (n=328) |
|
0.35 (0.24–0.50)*** |
DOACs (n=196) |
5.26 (3.36–8.24)*** |
2.92 (2.08–4.09)*** |
Fondaparinux (n=297) |
0.41 (0.25–0.67)*** |
|
Type of hospital |
University hospital (n=7025) |
2.29 (1.74–3.01)*** |
1.11 (1.01–1.23)* |
Scores |
PESI <85 points (n=4792) |
1.20 (0.98–1.47) |
1.33 (1.21–1.46)*** |
RIETE <1 point (n=3347) |
1.29 (1.04–1.60)* |
1.57 (1.42–1.74)*** |
ACCP scheme ≤1 point (n=1759)¶ |
1.29 (0.98–1.69) |
1.46 (1.28–1.66)*** |